
LFCR Stock Forecast & Price Target
LFCR Analyst Ratings
Bulls say
Lifecore Biomedical has demonstrated notable growth in its HA manufacturing segment, primarily driven by favorable order timing from its largest customer, indicating strong demand for its services. The company is positioned for significant operational momentum, with expectations of meaningful commercial revenue generation as early as 2027, paving the way for a potential breakout year in 2028. Additionally, Lifecore aims to increase its capacity utilization from 20% in 2025 to 60% by 2029, supporting a targeted revenue compound annual growth rate (CAGR) of 12%, which highlights the company's positive outlook in the medium to long term.
Bears say
Lifecore Biomedical has experienced a significant decline in share price, dropping over 50% in the past two months, primarily attributed to disappointing fiscal year 2026 guidance and conservative expectations for fiscal year 2027 top-line growth. The company reported a noticeable decline in CDMO revenue, driven by the absence of take-or-pay arrangements and decreased aseptic sales volumes, amid a challenging revenue landscape compounded by a $17 million to $18 million headwind from customer losses, inventory rebalancing, and delayed product launches. Additionally, uncertainties regarding the potential need for a capital raise further contribute to a cautious outlook on the company's financial stability and performance prospects.
This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.
LFCR Analyst Forecast & Price Prediction
Start investing in LFCR
Order type
Buy in
Order amount
Est. shares
0 shares